SPECT radiopharmaceuticals for dementia

Area of Science:

• Neuroimaging
• Nuclear Medicine
• Neurology

Background:

• Interest in functional neuroimaging for neurodegenerative diseases has grown significantly.
• Current dementia diagnosis relies heavily on clinical assessments.
• Various neuroimaging modalities investigate different aspects of neurodegeneration.

Purpose of the Study:

• To highlight the evolving role of Single-photon emission computed tomography (SPECT) in neuroimaging.
• To discuss advancements in SPECT technology and radiopharmaceuticals.
• To explore the potential for SPECT to maintain clinical relevance in diagnosing neurodegenerative diseases.

Main Methods:

• Review of recent developments in SPECT imaging systems, including integration with MRI, CT, and ultrasound.
• Analysis of ongoing research into new SPECT radiotracers, dual-SPECT techniques, and receptor-targeting radiopharmaceuticals.
• Evaluation of the impact of these advancements on SPECT's diagnostic capabilities.

Main Results:

• Despite predictions of its decline, SPECT imaging is experiencing innovation.
• Development of new SPECT systems with improved imaging capabilities and multi-modality integration.
• Advancement in SPECT radiotracers and radiopharmaceuticals is expanding its potential applications.

Conclusions:

• SPECT imaging continues to be a valuable tool in neuroimaging for neurodegenerative diseases.
• Technological and radiopharmaceutical advancements are poised to enhance SPECT's clinical applications.
• SPECT's integration with other modalities offers improved diagnostic insights.